SAN DIEGO, CA--(Marketwire - Oct 29, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., will be presenting today at the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum, the regenerative medicine industry's premier business development and partnering meeting. The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industry's most exciting technologies. Thirty-five companies and organizations will be presented over the course of 2 days, ranging from translational research centers to emerging-growth biotech companies, as well as established, publicly traded industry leaders.
The following are specific details regarding Regen BioPharma's presentation at the conference:
October 29th, 2012
Sanford Consortium for Regenerative Medicine Building
Auditorium, Second Floor Terrace
2880 Torrey Pines Scenic Drive, La Jolla, California
The Investor and Partnering Forum was created in 2011 to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. It will be held immediately prior to the Stem Cell Meeting on the Mesa's Scientific Symposium organized by the Sanford Consortium, and the combined meetings are expected to attract over 800 attendees from around the globe. The company presentations will be recorded by ARM and will be made available on ARM's website shortly after the event. To learn more or to register for the 2012 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit www.stemcellmeetingonthemesa.com.
About Bio-Matrix Scientific Group, Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) is a biotechnology company developing regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group, Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.